DailyDoctor Archive Specialties Get app
Back to the 7 September 2026 edition

Clinical update · 01 of 05

Rheumatoid arthritis-associated lung disease: consensus where the evidence will not support a guideline

An expert group has issued consensus statements on screening for, diagnosing and treating rheumatoid arthritis-associated interstitial lung disease — useful for building a joint pathway with rheumatology, but consensus rather than trial evidence, and it says so.

Interstitial lung disease is a common and serious complication of rheumatoid arthritis, and there has been no agreement on how to look for it, when to treat, or with what. This international multidisciplinary group set out to fix the first problem without pretending to have solved the second: they state openly that high-quality studies are too scarce to support strict evidence-based guidelines, so they synthesised the evidence qualitatively and issued consensus statements covering risk factors, screening for interstitial lung disease in rheumatoid arthritis, and treatment of established disease.

That framing is the honest part and should govern how the document is used. A consensus statement records what experienced clinicians agree on when the trials do not exist. It is a reasonable basis for building a local screening pathway where none exists, and a poor basis for overriding a clinical judgement made in front of the patient.

The practical value is in having something to point to. Rheumatology and respiratory services frequently disagree about who should be scanned and when, and the disagreement is usually resolved by whoever is more insistent rather than by evidence. A named consensus on risk factors and screening gives both services the same starting document, and it gives the patient with rheumatoid arthritis, a cough and no obvious cause a defined route rather than a referral loop.

  • Use it to agree a joint rheumatology-respiratory screening pathway rather than as a rule for the individual patient
  • Read the risk-factor statements first — they determine who enters the pathway at all
  • Treat the treatment statements as expert opinion, and say so when quoting them to a patient
  • Set a monitoring interval explicitly at diagnosis; progression is what the statements are designed to catch
  • A patient with rheumatoid arthritis and unexplained breathlessness or cough warrants assessment regardless of what a screening threshold says

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

ildasthmacopdoccupational

Tomorrow morning, before your first patient

One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app